BML-260
BML-260 is a potent inhibitor of dual-specific phosphatases JSP-1 and DUSP22. BML-260 can activate UCP1 and thermogenesis in adipocytes in a JSP-1-independent manner. The effect of BML-260 on adipocytes is partially achieved through the activation of CREB, STAT3, and PPAR signaling pathways. BML-260 can be used in the research of inflammatory and proliferative disorders associated with JNK signaling dysfunction as well as obesity[1][2].
Product Specifications
CAS Number
101439-76-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
PPAR; STAT
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; JAK/STAT Signaling; Metabolic Enzyme/Protease; Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bml-260.html
Purity
99.65
Solubility
DMSO : 14.29 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(O)C1=CC=C(N(C/2=O)C(SC2=C\C3=CC=CC=C3)=S)C=C1
Molecular Formula
C17H11NO3S2
Molecular Weight
341.40
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ASPG sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
